ClinicalTrials.gg
RecruitingNCT07218809TREVI-OC-01Updated Jul 21, 2026

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

A Phase 3 interventional study of AZD5335 and Mirvetuximab Soravtansine (MIRV) in Epithelial Ovarian Cancer, sponsored by AstraZeneca. Recruiting at 299 sites in 24 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States — 29 open to participants now, 50 under way, 8 of them phase 3. Carcinoma, Ovarian Epithelial · United States.

Planned enrollment
5th of 381
1,100 · median 35
Started
2025
with 6 others
Phase 3
37 of 500
5 open now
Primary completion
2028-11
later than 38 of 49 live
Registered
493rd of 500
by date

Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, this one is the 5th largest by planned enrollment of the 381 interventional ones that give a count, is one of 7 that started in 2025, is one of 37 in phase 3, reaches primary completion later than 38 of the 49 other live ones, and was the 493rd registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

29 of the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, or all of them as a file.
02

Study summary

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.

Read the detailed description

Approximately 1100 adult participants will be enrolled after central FRα testing into two independent cohorts (about 550 FRα-high and 550 FRα-low) and randomized 1:1 within each cohort to receive AZD5335 or the relevant standard of care (mirvetuximab soravtansine in FRα-high; investigator's choice single-agent chemotherapy in FRα-low). Participants will remain on assigned treatment and undergo regular tumor evaluations per RECIST v1.1 until disease progression or another reason for treatment discontinuation.

All participants will be followed for overall survival. An independent data monitoring committee (IDMC) of external experts will periodically review unblinded safety and interim efficacy to confirm participant safety and study integrity.

03

Conditions studied

  • Epithelial Ovarian Cancer

Keywords

  • Epithelial Ovarian Cancer
  • Peritoneal Cancer
  • Follopian Tube Cancer
  • Platinum Resistant Ovarian Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria

  • Participants with confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer.
  • Participants must have platinum-resistant disease:
  • Participants who have only had one prior line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (CR or PR) and then progressed between > 3 months and ≤ 6 months after the date of the last dose of platinum.
  • Participants who have received 2 or 3 lines of platinum therapy must have progressed ≤ 6 months after the date of the last dose of platinum.
  • Participants must have radiologically progressed on or after their most recent .
  • Participants must have received at least one, but no more than 3, prior systemic lines of anti-cancer therapy, and for whom single-agent therapy is appropriate as the next line of treatment
  • Participants with documented BRCA mutation (germline and/or somatic) must have received prior PARPi if the participant is eligible per approved label and standard-of-care institutional guidelines, except in cases of documented , precaution or intolerance.
  • Provision of an FFPE tumour tissue sample

Key Exclusion criteria

  • Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumours containing any of the above histologies, or low-grade or borderline ovarian tumour.
  • Primary platinum- disease, defined as disease that did not respond to or has progressed ≤ 3 months after the last dose of first line platinum-containing chemotherapy.
  • Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring
  • Current signs, symptoms, or clinical investigations consistent with bowel obstruction, including sub-occlusive disease.
  • Participant has non-infectious ILD/pneumonitis or has a history of non-infectious ILD/pneumonitis that required oral or IV or supplemental oxygen, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Prior treatment with any FRα-targeted therapy, including MIRV, or any TOP1i ADC.
  • Major surgical procedure within 4 weeks of the first dose of study intervention
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,100 participants (estimated)

Study arms

  • Experimental
    AZD5335 in FRa-high cohort

    AZD5335 IV (intravenous) in FRa-high cohort

    Drug: AZD5335

  • Active comparator
    Mirvetuximab Soravtansine (MIRV) in FRa-high cohort

    MIRV AIBW IV in FRa-high cohort

    Drug: Mirvetuximab Soravtansine (MIRV)

  • Experimental
    AZD5335 in FRa-low cohort

    AZD5335 IV (intravenous) in FRa-low cohort

    Drug: AZD5335

  • Active comparator
    Investigator´s choice chemotherapy in FRa-low cohort

    Investigator's choice of chemotherapy Paclitaxel IV Pegylated liposomal Doxorubicin (PLD) IV or Topotecan IV in FRa-low cohor

    Drug: Paclitaxel · Drug: Pegylated liposomal Doxorubicin (PLD) · Drug: Topotecan

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free Survival (PFS)

    PFS is defined as the time from randomization to radiographic progression as assessed by the Investigator per RECIST v1.1, or death due to any cause.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Overall survival (OS)

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Up to approximately 5 years

Other outcomes

  1. Second progression free survival (PFS2)

    Time from randomization to second progression or death (PFS2) is defined as the time from randomization to the earliest progression event (following the initial progression) subsequent to the first subsequent therapy, or death.

    Time frame: Up to approximately 5 years

  2. Objective response date (ORR)

    ORR is defined as the proportion of participants who have a complete or partial response, as determined by the investigator, per RECIST v1.1.

    Time frame: Up to approximately 5 years

  3. Duration of response (DoR)

    DoR is defined as the time from the date of first documented response until the date of documented progression per RECIST v1.1, as assessed by the investigator, or death due to any cause.

    Time frame: Up to approximately 5 years

  4. Health-related Quality of Life (HrQoL)

    Change from baseline in selected subscales of EORTC QLQ C30; global health status, physical function and EORTC QLQ OV28 hormonal symptoms (EORTC IL).

    Time frame: Up to approximately 5 years

  5. CA-125 Response Rate (CA-125 RR)

    Proportion of participants achieving CA-125 response per GCIG criteria

    Time frame: Up to approximately 5 years

07

Study locations

95 of 299 sites recruiting
  • Research Site
    Birmingham, Alabama 35223, United States
    Recruiting
  • Research Site
    Little Rock, Arkansas 72205, United States
    Not yet recruiting
  • Research Site
    La Jolla, California 92037, United States
    Not yet recruiting
  • Research Site
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Research Site
    Fort Lauderdale, Florida 33316, United States
    Not yet recruiting
  • Research Site
    Gainesville, Florida 32608, United States
    Recruiting
  • Research Site
    Jupiter, Florida 33458, United States
    Recruiting
  • Research Site
    Miami, Florida 33176, United States
    Recruiting
  • Research Site
    Weston, Florida 33331, United States
    Not yet recruiting
  • Research Site
    Chicago, Illinois 60612, United States
    Not yet recruiting
  • Research Site
    Evanston, Illinois 60201, United States
    Not yet recruiting
  • Research Site
    Peoria, Illinois 61637, United States
    Recruiting
  • Research Site
    Urbana, Illinois 61801, United States
    Recruiting
  • Research Site
    Fort Wayne, Indiana 46845, United States
    Recruiting
  • Research Site
    Indianapolis, Indiana 46202, United States
    Recruiting
  • Research Site
    Louisville, Kentucky 40241, United States
    Recruiting
  • Research Site
    Towson, Maryland 21204, United States
    Recruiting
  • Research Site
    Burlington, Massachusetts 01805, United States
    Recruiting
  • Research Site
    Worcester, Massachusetts 01655, United States
    Not yet recruiting
  • Research Site
    Minneapolis, Minnesota 55404, United States
    Recruiting
  • Research Site
    Springfield, Missouri 65807, United States
    Recruiting
  • Research Site
    Billings, Montana 59106, United States
    Recruiting
  • Research Site
    Omaha, Nebraska 68114, United States
    Recruiting
  • Research Site
    Las Vegas, Nevada 89106, United States
    Recruiting
  • Research Site
    Lebanon, New Hampshire 03756, United States
    Not yet recruiting
  • Research Site
    Camden, New Jersey 08103, United States
    Not yet recruiting
  • Research Site
    The Bronx, New York 10461, United States
    Not yet recruiting
  • Research Site
    Chapel Hill, North Carolina 27599, United States
    Recruiting
  • Research Site
    Blue Ash, Ohio 45242, United States
    Recruiting
  • Research Site
    Dayton, Ohio 45459, United States
    Recruiting
  • Research Site
    Sylvania, Ohio 43560, United States
    Not yet recruiting
  • Research Site
    Portland, Oregon 97213, United States
    Recruiting
  • Research Site
    York, Pennsylvania 17403, United States
    Not yet recruiting
  • Research Site
    Germantown, Tennessee 38138, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Research Site
    Tyler, Texas 75702, United States
    Recruiting
  • Research Site
    Salt Lake City, Utah 84106, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site
    Roanoke, Virginia 24016, United States
    Recruiting
  • Research Site
    Seattle, Washington 98104, United States
    Recruiting
  • Research Site
    Adelaide, 5037, Australia
    Recruiting
  • Research Site
    Auchenflower, 4066, Australia
    Recruiting
  • Research Site
    Campbelltown, 2560, Australia
    Recruiting
  • Research Site
    Camperdown, 2050, Australia
    Not yet recruiting
  • Research Site
    Clayton, 3168, Australia
    Not yet recruiting
  • Research Site
    Cudgen, 2487, Australia
    Not yet recruiting
  • Research Site
    Garran, 2605, Australia
    Recruiting
  • Research Site
    Gosford, 2250, Australia
    Recruiting
  • Research Site
    Heidelberg, 3084, Australia
    Recruiting
  • Research Site
    Kogarah, 2217, Australia
    Recruiting
  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Richmond, 3121, Australia
    Recruiting
  • Research Site
    St Leonards, 2065, Australia
    Recruiting
  • Research Site
    Waratah, 2298, Australia
    Recruiting
  • Research Site
    Charleroi, 6060, Belgium
    Not yet recruiting
  • Research Site
    Edegem, 2650, Belgium
    Not yet recruiting
  • Research Site
    Ghent, 9000, Belgium
    Recruiting
  • Research Site
    Leuven, 3000, Belgium
    Recruiting
  • Research Site
    Libramont-Chevigny, 6800, Belgium
    Recruiting
  • Research Site
    Namur, 5000, Belgium
    Recruiting
  • Research Site
    Barretos, 14784-400, Brazil
    Not yet recruiting
  • Research Site
    Bela Vista, 1317, Brazil
    Not yet recruiting
  • Research Site
    Curitiba, 81520-060, Brazil
    Not yet recruiting
  • Research Site
    Goiânia, 74110-060, Brazil
    Not yet recruiting
  • Research Site
    Natal, 59075-740, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 90020-090, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 90035-903, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 90610-000, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 91350200, Brazil
    Not yet recruiting
  • Research Site
    Porto Velho, 76834-899, Brazil
    Not yet recruiting
  • Research Site
    Rio de Janeiro, 20230-130, Brazil
    Not yet recruiting
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 01401-002, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 01409-902, Brazil
    Not yet recruiting
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
    Not yet recruiting
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
    Not yet recruiting
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
    Not yet recruiting
  • Research Site
    Québec, G1G 5X1, Canada
    Not yet recruiting
  • Research Site
    Port Montt, 5480000, Chile
    Not yet recruiting
  • Research Site
    Providencia, 7510032, Chile
    Not yet recruiting
  • Research Site
    Santiago, 7500587, Chile
    Not yet recruiting
  • Research Site
    Santiago, 7500653, Chile
    Not yet recruiting
  • Research Site
    Santiago, 7520426, Chile
    Not yet recruiting
  • Research Site
    Santiago, 8330032, Chile
    Not yet recruiting
  • Research Site
    Santiago, 8331143, Chile
    Not yet recruiting
  • Research Site
    Santiago, 8420383, Chile
    Not yet recruiting
  • Research Site
    Viña del Mar, 2520000, Chile
    Not yet recruiting
  • Research Site
    Beijing, 100021, China
    Not yet recruiting
  • Research Site
    Beijing, 100142, China
    Not yet recruiting
  • Research Site
    Beijing, 102600, China
    Not yet recruiting
  • Research Site
    Bengbu, 233004, China
    Not yet recruiting
  • Research Site
    Changchun, 130012, China
    Not yet recruiting
  • Research Site
    Changsha, 410008, China
    Not yet recruiting
  • Research Site
    Changsha, 410013, China
    Not yet recruiting
  • Research Site
    Chengdu, 610041, China
    Not yet recruiting
  • Research Site
    Chongqing, 400030, China
    Not yet recruiting
  • Research Site
    Fuzhou, 350011, China
    Not yet recruiting

Showing the first 100 of 299 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared. AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment https://vivli.org/. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2028, 34 months after the start.

Of 33 phase 3 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2025
First posted
Oct 20, 2025
StartActual
Dec 29, 2025
Primary completionEst.
Nov 17, 2028
CompletionEst.
Dec 27, 2029
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07218809
Lead sponsor
AstraZeneca
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Ventana Medical Systems, Inc
Responsible party
Sponsor
First posted
Oct 20, 2025
Start date
Dec 29, 2025
Primary completion
Nov 17, 2028 (estimated)
Completion
Dec 27, 2029 (estimated)
Last update
Jul 21, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Torvutatug samrotecan

Start the discussion